OraPharma, Inc.’s ARESTIN® Honored for the Sixth Consecutive Year with Coveted 2009 Townie Choice Award

Warminster, PA (February 4, 2010) − OraPharma, Inc., a specialty oral health company dedicated to bringing scientific and technological products to the dental community, recently announced that its ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg continues to be regarded as the standard of care for locally administered antibiotics (LAA) used as a part of comprehensive periodontal disease treatment by dentists and hygienists alike.
For the sixth year in a row, ARESTIN® was overwhelmingly named the LAA of choice in the 2009 Townie Choice Awards from Dentaltown, and is featured in the December 2009 issue. ARESTIN® is indicated as an adjunct treatment to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.
The Townie Choice Awards were created to provide dental professionals with a peer-driven source of information when making difficult purchase decisions. What’s more, the Townie Choice Award is the only honor in dentistry that is bestowed directly from the clinicians who treat patients every day.
“Each product chosen by our readers plays an important part in their everyday professional success based on positive patient outcomes,” remarked Thomas Giacobbi, DDS, FAGD, editorial director, Dentaltown. “The Townie Choice Awards are very influential and provide an accurate profile of our Dentaltown community product loyalties.”
“We’re pleased and honored that ARESTIN® is consistently selected by dental professionals as an essential part of their standard of care when treating periodontal disease,” said OraPharma’s Product Director, ARESTIN®, Ben Sandefur. “We are dedicated to continuing this trend in 2010 with ongoing efforts to increase awareness of periodontal disease and the need for comprehensive periodontal disease treatment.”

For a complete list of all winning Townie Choice products, please pick up the December 2009 issue of Dentaltown, or log onto www.dentaltown.com.

About OraPharma, Inc.
OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg (www.myarestin.com) is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. OSSIX™ PLUS™ (resorbable collagen membrane) is used in guided bone regeneration (GBR) and guided tissue regeneration (GTR) procedures. For more information about OraPharma and its products, visit www.orapharma.com.

About ARESTIN®
ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.

ARESTIN® contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.

The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.

ARESTIN® and OSSIX™ PLUS™ are trademarks of OraPharma, Inc.